Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

SELLAS Reports Prelim. Data Showing Clinical Benefits From Phase 1/2 Trial Of Galinpepimut-S In Combo With Keytruda For Advance Ovarian Cancer: Median Overall Survival Not Reached At A Median Follow Up Of 43.1 Weeks

By Benzinga Newsdesk
Today, 2:39 AM
  - Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a checkpoint  - Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone -

MRK